AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.47+1.54 (+1.41%) ▲|ACN187.68-0.41 (-0.22%) ▼|ADBE279.79-6.29 (-2.20%) ▼|AMAT438.46-3.39 (-0.77%) ▼|AMD457.06-2.55 (-0.55%) ▼|AMGN442.84+4.72 (+1.08%) ▲|AMT172.92-3.10 (-1.76%) ▼|AMZN254.98+0.06 (+0.02%) ▲|AVGO367.24-2.44 (-0.66%) ▼|AXP329.98+5.79 (+1.79%) ▲|BA208.87+3.21 (+1.56%) ▲|BAC62.60+0.61 (+0.98%) ▲|BKNG199.60+3.91 (+2.00%) ▲|BLK1,107.08-21.02 (-1.86%) ▼|BMY67.66+0.74 (+1.11%) ▲|BNY162.04+1.53 (+0.95%) ▲|BRK-B505.24+2.91 (+0.58%) ▲|C134.34+1.80 (+1.36%) ▲|CAT792.28+13.12 (+1.68%) ▲|CL90.10+0.47 (+0.52%) ▲|CMCSA26.81+0.51 (+1.94%) ▲|COF216.60+5.26 (+2.49%) ▲|COP137.20+1.01 (+0.74%) ▲|COST928.48-11.48 (-1.22%) ▼|CRM256.93-1.18 (-0.46%) ▼|CSCO109.46-0.29 (-0.26%) ▼|CVS97.23-0.37 (-0.38%) ▼|CVX211.78+0.73 (+0.35%) ▲|DE698.37+22.29 (+3.30%) ▲|DHR209.91+2.98 (+1.44%) ▲|DIS107.98+1.76 (+1.66%) ▲|DUK120.56+0.17 (+0.14%) ▲|EMR148.98+1.35 (+0.91%) ▲|FDX316.54-8.34 (-2.57%) ▼|GD364.07-5.34 (-1.45%) ▼|GE329.50-1.59 (-0.48%) ▼|GEV921.94+23.41 (+2.61%) ▲|GILD149.61-0.31 (-0.21%) ▼|GM84.87-0.76 (-0.89%) ▼|GOOG333.78+1.75 (+0.53%) ▲|GOOGL337.12+2.10 (+0.63%) ▲|GS1,004.42+1.86 (+0.19%) ▲|HD318.51-1.26 (-0.39%) ▼|HON206.07-3.91 (-1.86%) ▼|IBM231.70+0.30 (+0.13%) ▲|INTC90.05+1.08 (+1.21%) ▲|INTU342.94-1.99 (-0.58%) ▼|ISRG371.88+2.63 (+0.71%) ▲|JNJ275.21+4.02 (+1.48%) ▲|JPM356.22+1.27 (+0.36%) ▲|KO88.24+0.24 (+0.27%) ▲|LIN487.45+0.69 (+0.14%) ▲|LLY1,160.08+0.08 (+0.01%) ▲|LMT531.55-12.95 (-2.38%) ▼|LOW199.84-0.21 (-0.11%) ▼|LRCX288.32-1.88 (-0.65%) ▼|MA588.14+7.04 (+1.21%) ▲|MCD260.95-0.16 (-0.06%) ▼|MDLZ62.45+0.84 (+1.36%) ▲|MDT92.18+0.14 (+0.15%) ▲|META592.85+14.31 (+2.47%) ▲|MMM168.75-1.49 (-0.88%) ▼|MO69.56-0.01 (-0.01%) ▼|MRK151.64+1.78 (+1.19%) ▲|MS211.82+0.78 (+0.37%) ▲|MSFT496.82-4.20 (-0.84%) ▼|MU956.08+22.64 (+2.43%) ▲|NEE83.10+0.17 (+0.21%) ▲|NFLX82.73+1.92 (+2.38%) ▲|NKE38.24+0.12 (+0.31%) ▲|NOW136.72-6.18 (-4.32%) ▼|NVDA224.41+6.97 (+3.21%) ▲|ORCL145.75+4.43 (+3.13%) ▲|PEP140.52+0.73 (+0.52%) ▲|PFE29.02+0.47 (+1.65%) ▲|PG147.64+1.43 (+0.98%) ▲|PLTR169.46-10.46 (-5.81%) ▼|PM187.94+0.79 (+0.42%) ▲|QCOM169.96+3.35 (+2.01%) ▲|RTX200.78-4.38 (-2.13%) ▼|SBUX106.72+0.57 (+0.54%) ▲|SCHW108.24-0.04 (-0.04%) ▼|SO88.31+0.22 (+0.25%) ▲|SPG210.20-1.67 (-0.79%) ▼|T25.95-0.05 (-0.19%) ▼|TMO608.54+8.04 (+1.34%) ▲|TMUS187.30+5.14 (+2.82%) ▲|TSLA357.01+0.92 (+0.26%) ▲|TXN254.80+1.46 (+0.58%) ▲|UBER76.45+1.21 (+1.61%) ▲|UNH399.66+3.36 (+0.85%) ▲|UNP289.73-0.89 (-0.31%) ▼|UPS103.01+0.35 (+0.34%) ▲|USB62.77+1.56 (+2.55%) ▲|V378.40+5.73 (+1.54%) ▲|VZ50.22-0.08 (-0.16%) ▼|WFC89.27+2.23 (+2.56%) ▲|WMT106.09+0.17 (+0.16%) ▲|XOM164.15-0.40 (-0.24%) ▼|AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.47+1.54 (+1.41%) ▲|ACN187.68-0.41 (-0.22%) ▼|ADBE279.79-6.29 (-2.20%) ▼|AMAT438.46-3.39 (-0.77%) ▼|AMD457.06-2.55 (-0.55%) ▼|AMGN442.84+4.72 (+1.08%) ▲|AMT172.92-3.10 (-1.76%) ▼|AMZN254.98+0.06 (+0.02%) ▲|AVGO367.24-2.44 (-0.66%) ▼|AXP329.98+5.79 (+1.79%) ▲|BA208.87+3.21 (+1.56%) ▲|BAC62.60+0.61 (+0.98%) ▲|BKNG199.60+3.91 (+2.00%) ▲|BLK1,107.08-21.02 (-1.86%) ▼|BMY67.66+0.74 (+1.11%) ▲|BNY162.04+1.53 (+0.95%) ▲|BRK-B505.24+2.91 (+0.58%) ▲|C134.34+1.80 (+1.36%) ▲|CAT792.28+13.12 (+1.68%) ▲|CL90.10+0.47 (+0.52%) ▲|CMCSA26.81+0.51 (+1.94%) ▲|COF216.60+5.26 (+2.49%) ▲|COP137.20+1.01 (+0.74%) ▲|COST928.48-11.48 (-1.22%) ▼|CRM256.93-1.18 (-0.46%) ▼|CSCO109.46-0.29 (-0.26%) ▼|CVS97.23-0.37 (-0.38%) ▼|CVX211.78+0.73 (+0.35%) ▲|DE698.37+22.29 (+3.30%) ▲|DHR209.91+2.98 (+1.44%) ▲|DIS107.98+1.76 (+1.66%) ▲|DUK120.56+0.17 (+0.14%) ▲|EMR148.98+1.35 (+0.91%) ▲|FDX316.54-8.34 (-2.57%) ▼|GD364.07-5.34 (-1.45%) ▼|GE329.50-1.59 (-0.48%) ▼|GEV921.94+23.41 (+2.61%) ▲|GILD149.61-0.31 (-0.21%) ▼|GM84.87-0.76 (-0.89%) ▼|GOOG333.78+1.75 (+0.53%) ▲|GOOGL337.12+2.10 (+0.63%) ▲|GS1,004.42+1.86 (+0.19%) ▲|HD318.51-1.26 (-0.39%) ▼|HON206.07-3.91 (-1.86%) ▼|IBM231.70+0.30 (+0.13%) ▲|INTC90.05+1.08 (+1.21%) ▲|INTU342.94-1.99 (-0.58%) ▼|ISRG371.88+2.63 (+0.71%) ▲|JNJ275.21+4.02 (+1.48%) ▲|JPM356.22+1.27 (+0.36%) ▲|KO88.24+0.24 (+0.27%) ▲|LIN487.45+0.69 (+0.14%) ▲|LLY1,160.08+0.08 (+0.01%) ▲|LMT531.55-12.95 (-2.38%) ▼|LOW199.84-0.21 (-0.11%) ▼|LRCX288.32-1.88 (-0.65%) ▼|MA588.14+7.04 (+1.21%) ▲|MCD260.95-0.16 (-0.06%) ▼|MDLZ62.45+0.84 (+1.36%) ▲|MDT92.18+0.14 (+0.15%) ▲|META592.85+14.31 (+2.47%) ▲|MMM168.75-1.49 (-0.88%) ▼|MO69.56-0.01 (-0.01%) ▼|MRK151.64+1.78 (+1.19%) ▲|MS211.82+0.78 (+0.37%) ▲|MSFT496.82-4.20 (-0.84%) ▼|MU956.08+22.64 (+2.43%) ▲|NEE83.10+0.17 (+0.21%) ▲|NFLX82.73+1.92 (+2.38%) ▲|NKE38.24+0.12 (+0.31%) ▲|NOW136.72-6.18 (-4.32%) ▼|NVDA224.41+6.97 (+3.21%) ▲|ORCL145.75+4.43 (+3.13%) ▲|PEP140.52+0.73 (+0.52%) ▲|PFE29.02+0.47 (+1.65%) ▲|PG147.64+1.43 (+0.98%) ▲|PLTR169.46-10.46 (-5.81%) ▼|PM187.94+0.79 (+0.42%) ▲|QCOM169.96+3.35 (+2.01%) ▲|RTX200.78-4.38 (-2.13%) ▼|SBUX106.72+0.57 (+0.54%) ▲|SCHW108.24-0.04 (-0.04%) ▼|SO88.31+0.22 (+0.25%) ▲|SPG210.20-1.67 (-0.79%) ▼|T25.95-0.05 (-0.19%) ▼|TMO608.54+8.04 (+1.34%) ▲|TMUS187.30+5.14 (+2.82%) ▲|TSLA357.01+0.92 (+0.26%) ▲|TXN254.80+1.46 (+0.58%) ▲|UBER76.45+1.21 (+1.61%) ▲|UNH399.66+3.36 (+0.85%) ▲|UNP289.73-0.89 (-0.31%) ▼|UPS103.01+0.35 (+0.34%) ▲|USB62.77+1.56 (+2.55%) ▲|V378.40+5.73 (+1.54%) ▲|VZ50.22-0.08 (-0.16%) ▼|WFC89.27+2.23 (+2.56%) ▲|WMT106.09+0.17 (+0.16%) ▲|XOM164.15-0.40 (-0.24%) ▼|
21.5 C
New York
Thursday, September 3, 2026

Tag: lead

newssourceFORcompanyinformationcontent1releasesmarket

A New Lease of Life: Stories of Hope, Survivorship and Second Chances with Apollo Hospitals

Cancer changes lives long before it changes medical reports.NEW DELHI , June 8, 2026 /PRNewswire/ -- It disrupts routines, alters plans, and tests families in...

ROSEN, LEADING INVESTOR COUNSEL, Encourages Calix, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CALX

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Calix, Inc. (NYSE: CALX) between January 28, 2026 and April 21, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

The OREO Brand & BTS Movement is On! Introducing the Limited Edition OREO & BTS Cookies

BTS is sharing a taste of their Korean roots through a new OREO cookie they created.The OREO cookie offers a taste of BTS's home...

Vi Appoints Spencer Honeyman as President, Global Growth

NEW YORK, June 7, 2026 /PRNewswire/ -- Vi today announced the promotion of Spencer Honeyman to President, Global Growth. ...

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes...

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PHR

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”), of the important July 13, 2026 lead plaintiff deadline.

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VERI

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the important July 20, 2026 lead plaintiff deadline.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLead

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers